Vector® TrueVIEW® Autofluorescence Quenching Kit

SKU Unit Size Price Qty
SP-8400-15 15 ml

To request a quote for products:

  1. Click “Contact Us” in the header bar above;
  2. Click “Customer Service”;
  3. Complete the form and provide the following information in the “Comments” section: note you would like a quote, item number (SKU) and quantity;
  4. Click “Submit”.


The Vector TrueVIEW Autofluorescence Quenching Kit provides a novel way to diminish unwanted autofluorescence from non-lipofuscin sources and dramatically improve signal-to-noise ratio. It removes unwanted autofluorescence in tissue sections due to aldehyde fixation, red blood cells, and structural elements such as collagen and elastin. The quenching action of the kit reagents provides a clear, unambiguous, “true view” localization of the target antigen.


  • Effective on problematic tissues such as kidney and spleen
  • Easy-to-use, one-step method
  • Compatible with a wide selection of fluorophores
  • Compatible with standard epifluorescence and confocal laser microscopes
  • TrueVIEW with DAPI counterstain available here


One kit is sufficient to treat approximately 100 to 150 tissue sections. 


More Information
Unit Size 15 ml
Applications Immunofluorescence, In situ hybridization
Blocking Action Autofluorescence
Format Concentrate

Kit Components

Kit Contents:

  • Vector TrueVIEW Reagent A, 5 ml
  • Vector TrueVIEW Reagent B, 5 ml
  • Vector TrueVIEW Reagent C, 5 ml
  • VECTASHIELD® Vibrance™ Antifade Mounting Medium, 2 ml


Product FAQs

Why is the TrueVIEW™ Autofluorescence Quenching reagent applied after completion of the IF assay and not at the start of the procedure?

During product development, applying the TrueVIEW™ Quenching reagent at the end of our standard IF procedure yielded the most optimal reduction in autofluorescence signal. The reagent is retained on the tissue at the time of mounting, allowing for extended quenching action, with little to no effect on the specific fluorescent signal. However, in applications with very brief staining procedures, such as a primary antibody directly conjugated with a fluorophore, application of TrueVIEW™ Quenching reagent may be just as effective at the start of the procedure.

Do you have any published references describing the use of TrueVIEW Autofluorescence Quenching Kit?

There are a number of published references describing the use of TrueVIEW Autofluorescence Quenching Kit in the scientific literature. Below are some recent publications:Boucher, J.M., Robich, M., Scott, S.S. et al (2018). Rab27a Regulates Human Perivascular Adipose Progenitor Cell Differentiation. Cardiovasc Drugs Ther., ( Du, H. et al (2018). A novel mouse model of hemangiopericytoma due to loss of Tsc2. Human Mol. Gen., ( Su Y, Hou Y, Wang Q, (2018). The enhanced replication of an S-intact PEDV during coinfection with an S1 NTD-del PEDV in piglets, Veterinary Microbiology, ( Yoon, J.H., Li, M., Basile, J.R., Lin, Y (2018). Computer-assisted analysis of immunohistological parameters in oral giant cell granulomas, Oral Diseases, (

Is TrueVIEW effective against lipofuscin derived autofluorescence?

The working solution of TrueVIEW works in an electrostatic manner to greatly reduce or eliminate fluorescence in tissue sections induced through the use of an aldehyde based fixative. TrueVIEW is also effective at reducing fluorescence from tissue components such as collagen, elastin and red blood cells. TureVIEW does not work to reduce autofluorescence due to lipofuscin.

How long can I store the TrueVIEW working solution?

Once made up, the working solution of TrueVIEW can be stored either on the bench top or in the fridge (2-8C) fro about 48 hours (2 days) withut loss of activity or function. Following this time we would suggest discarding unused working solution and make fresh solution as required.

My tissue sections turned blue when I applied TrueVIEW. Is this supposed to happen?

Yes, the working solution is a blue color that does "stain" the tissue section blue. This indicates an active and appropriate chemical reaction is occurring. The blue stain on the section does not fluoresce and does not interfere with the immunofluorescence application.

What mounting media can I use with TrueVIEW?

Both TrueVIEW products, SP-8400 and SP-8500, are supplied with 2 mL of VECTASHIELD Vibrance antifade mounting media. We have found that the mounting media does play a crucial role in maintaining the high signal to noise ratio when using TrueVIEW. VECTASHIELD Vibrance is included therefore as a critical component of the kit and it is recommended to use the media supplied for optimal results. At this time we do not have sufficient data to confidently recommend the use of other vendors mounting media with TrueVIEW. Substitution of VECTASHIELD Vibrance with another mounting media may result in less than satisfactory results.

For the wash step after applying the TrueVIEW quenching reagent, can I use buffers other than PBS or detergents??

No, we have found that the TrueVIEW reagent lifts off the tissue using TBS or HEPES buffer. Detergents are incompatible.

Technical Information

Tissue autofluorescence often occurs with aldehyde fixation or from inherent native tissue components (collagen, elastin, and red blood cells). The extent and intensity of autofluorescence background frequently makes it difficult or impossible to distinguish specific signals in immunofluorescence applications.

Most methods for reduction of tissue autofluorescence act primarily on lipofuscin granules, and are not broadly effective against the most common sources of autofluorescence targeted by Vector TrueVIEW Quencher.

Current methods for reducing autofluorescence primarily include “home brew” concoctions such as sodium borohydride and other ink-based products. These methods are essentially ineffective against aldehyde induced autofluorescence.  In contrast, Vector TrueVIEW reagent binds to hydrophilic compounds and effectively quenches endogenous autofluorescence. 


  1. Blanco, S. et al. 2020. Hyaluronate Nanoparticles as a Delivery System to Carry Neuroglobin to the Brain after Stroke. Pharmaceutics  (

  2. Vinton, C.L. et al. 2019. Simian Immunodeficiency Virus Infection of Rhesus Macaques Results in Delayed Zika Virus Clearance. mBio (

  3. Oswald, D.M., Jones, M.B., Cobb, B.A. 2019.  Modulation of hepatocyte sialylation drives spontaneous fatty liver disease and inflammation. Glycobiology (

  4. Ushioda, W. et al. 2019. Neuropathology in Neonatal Mice After Experimental Coxsackievirus B2 Infection Using a Prototype Strain, Ohio-1. Journal of Neuropathology & Experimental Neurology  (

  5. Bencze, J., et al. 2019. Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer’s disease and neocortical Lewy body disease. Scientific Reports (

  6. Davies, S.P. et al. 2019. Hepatocytes Delete Regulatory T Cells by Enclysis, a CD4+ T Cell Engulfment Process. Cell Reports (

  7. Liebers, J. et al. 2019. 3D image analysis reveals differences of CD30 positive cells and network formation in reactive and malignant human lymphoid tissue (classical Hodgkin Lymphoma). PLoS One (

  8. Lecocq, Q. et al. 2019. Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules (

  9. Motoike, S. et al. 2019. Clumps of Mesenchymal Stem Cell/Extracellular Matrix Complexes Generated with Xeno-Free Conditions Facilitate Bone Regeneration via Direct and Indirect Osteogenesis. International Journal of Molecular Sciences (

  10. Wilson, M.R. et al. 2019. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nature Communications (

  11. Nagai-Okatani, C. et al. 2019. Wisteria floribunda agglutinin staining for the quantitative assessment of cardiac fibrogenic activity in a mouse model of dilated cardiomyopathy. Laboratory Investigation (

  12. Sheller-Miller, S. et al. 2019. Cyclic-recombinase-reporter mouse model to determine exosome communication and function during pregnancy. American Journal of Obstetrics and Gynecology (!)

  13. Abe, H. et al. 2019. Correlation between platelet thrombus formation on collagen-coated beads and platelet aggregation induced by ADP. Transfusion and Apheresis Science (

  14. Singh, B. et al. 2019. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy. Acta Neuropathologica (

  15. Chafe, S.C. et al. 2019. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res (

  16. Rhodes, S. et al. 2019. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Human Molecular Genetics (

  17. Rodgers, H.M. et al. 2019. Dopamine D1 and D3 receptor modulators restore morphine analgesia and prevent opioid preference in a model of neuropathic pain. Neuroscience (

  18. Yoon, J.H., Li, M., Basile, J.R., Lin, Y 2018. Computer-assisted analysis of immunohistological parameters in oral giant cell granulomas, Oral Diseases (

  19. Nishimura, A. et al. 2018. Hypoxia-induced interaction of filamin with Drp1 causes mitochondrial hyperfission–associated myocardial senescence. Science Signaling (

  20. Su Y, Hou Y, Wang Q. 2018. The enhanced replication of an S-intact PEDV during coinfection with an S1 NTD-del PEDV in piglets, Veterinary Microbiology (

  21. Soontornniyomkij, V. et al. 2018. Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS (

  22. Du, H. et al. 2018. A novel mouse model of hemangiopericytoma due to loss of Tsc2. Human Mol. Gen. (

  23. Boucher, J.M. et al. 2018. Rab27a regulates human perivascular adipose progenitor cell differentiation. Cardiovasc Drugs Ther. (

Spleen with-without TrueVIEW

Spleen (FFPE), antigen retrieved with Antigen Unmasking Solution, stained using Mouse Anti-CD20 (red) and Rabbit Anti-Ki67 (green), followed by VectaFluor™ Duet Kit, and mounted in VECTASHIELD Vibrance Mounting Medium with DAPI.  Left:  No TrueVIEW Quencher treatment - note interfereing autofluorescence.  Right:  Treated with TrueVIEW Autofluorescence Quencher.

No TrueVIEW Quencher => 20x objective, red channel exposed 200ms, green channel 200ms

With TrueVIEW Quencher => 20x objective, red channel exposed 200ms, green channel exposed 800ms


Spleen w-wo TrueVIEW Quencher Treatment

Pancreas (FFPE), antigen retrieved with Antigen Unmasking Solution, stained with Guinea Pig x Insulin (green) and Mouse x END (red), followed by FL-Goat x Guinea Pig IgG + Dylight® 594-Horse x Mouse IgG.  Mounted in VECTASHIELD Vibrance Mounting Medium with DAPI.

No TrueVIEW Quencher => 20x objective, red channel exposed 600ms, green channel 600ms

With TrueVIEW Quencher => 20x objective, red channel exposed 600ms, green channel exposed 600ms


Easy To Apply

Following completion of the IF staining procedure:

TrueVIEW Quencher How To


Mode of Action

Following completion of the IF staining procedure:

TrueVIEW Quencher mode of action


Signal to Noise Optimization

The primary antibody and detection reagents should be optimized (titered) in conjunction with Vector TrueVIEW Quenching Kit to achieve maximum signal to noise. 

TrueVIEW Primary Ab Optimization


Optimization of Exposure

Increasing exposure times may be necessary to achieve optimal image acquisition for TrueVIEW Quencher treated slides.

TrueView Optimization of Exposure



Comparison Between Vector TrueVIEW Reagent and Other Autofluorescence Reducing Agents

We compared the effectiveness of Vector TrueVIEW quenching action in parallel with other commercially available autofluorescence reducing products and "home brew" reagents, on serial sections of formalin-fixed, paraffin-embedded human pancreas visualized using a standard fluorescein (green) filter. No specific immunofluorescence staining was conducted. The images below highlight our results. All images were acquired under identical conditions (including microscope objective and exposure times). 

TrueVIEW Comparisons
TrueVIEW Time Course


 Customer Testimonials 

TrueVIEW Testimonials